Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > A message for the ones who doubt

<< Previous

Bullboard Posts

Next >>

Comment by grosdavidon May 05, 2020 5:27pm

191 Views

Post# 30990056

RE:RE:RE:A message for the ones who doubt

Shoosh don't be like the ignorant ones, two sucker punches...where? What we you hoping for? More approvals in every other country?

Rather filing clinical trials all around the world with no money or targeting the most appropriate countries with money?

Think, if you have investors crying because the stock droped 0,10$ in a week on a 5K$ investment, you think head of BMO capital markets will call the CEO and say : I'll buy that PP at whatever price you want?

Like honestly what are some of you guys crying about? Because your position in AGN is red? Because the PP dropped the stock? Because maybe some knew that the halt was coming?

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition